IDEAS home Printed from https://ideas.repec.org/r/nbr/nberte/0227.html
   My bibliography  Save this item

Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
  2. Wei Li & Nianbo Dong & Rebecca A. Maynard, 2020. "Power Analysis for Two-Level Multisite Randomized Cost-Effectiveness Trials," Journal of Educational and Behavioral Statistics, , vol. 45(6), pages 690-718, December.
  3. Stefano Conti & Karl Claxton, 2008. "Dimensions of design space: a decision-theoretic approach to optimal research design," Working Papers 038cherp, Centre for Health Economics, University of York.
  4. Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher, 2018. "Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 28-40, February.
  5. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100038, London School of Economics and Political Science, LSE Library.
  6. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
  7. Simon Eckermann & Andrew Willan, 2011. "Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies," PharmacoEconomics, Springer, vol. 29(7), pages 563-577, July.
  8. Raymond C. W. Hutubessy & Louis W. Niessen & Rob F. Dijkstra & Ton F. Casparie & Frans F. Rutten, 2005. "Stochastic league tables: an application to diabetes interventions in the Netherlands," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 445-455, May.
  9. Md Abu Manju & Math J. J. M. Candel & Gerard J. P. van Breukelen, 2019. "SamP2CeT: an interactive computer program for sample size and power calculation for two-level cost-effectiveness trials," Computational Statistics, Springer, vol. 34(1), pages 47-70, March.
  10. Klemen Naveršnik, 2015. "Output correlations in probabilistic models with multiple alternatives," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 133-139, March.
  11. Erin Kirwin & Ellen Rafferty & Kate Harback & Jeff Round & Christopher McCabe, 2021. "A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine," PharmacoEconomics, Springer, vol. 39(9), pages 1059-1073, September.
  12. Douglas Coyle & Martin J. Buxton & Bernie J. O'Brien, 2003. "Stratified cost‐effectiveness analysis: a framework for establishing efficient limited use criteria," Health Economics, John Wiley & Sons, Ltd., vol. 12(5), pages 421-427, May.
  13. David Brain & Jonathan Mitchell & James O’Beirne, 2020. "Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-13, June.
  14. Falk Schwendicke & Hendrik Meyer-Lueckel & Michael Stolpe & Christof Edmund Dörfer & Sebastian Paris, 2014. "Costs and Effectiveness of Treatment Alternatives for Proximal Caries Lesions," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-10, January.
  15. Mullahy, John, 2018. "Individual results may vary: Inequality-probability bounds for some health-outcome treatment effects," Journal of Health Economics, Elsevier, vol. 61(C), pages 151-162.
  16. Hammitt, James K., 2020. "Accounting for the distribution of benefits & costs in benefit-cost analysis," TSE Working Papers 20-1116, Toulouse School of Economics (TSE).
  17. James F. O’Mahony, 2020. "Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?," PharmacoEconomics, Springer, vol. 38(8), pages 777-779, August.
  18. Claxton, K. & Thompson, K. M., 2001. "A dynamic programming approach to the efficient design of clinical trials," Journal of Health Economics, Elsevier, vol. 20(5), pages 797-822, September.
  19. Manju, Md Abu & Candel, Math J.J.M. & van Breukelen, Gerard J.P., 2021. "Robustness of cost-effectiveness analyses of cluster randomized trials assuming bivariate normality against skewed cost data," Computational Statistics & Data Analysis, Elsevier, vol. 157(C).
  20. Shiell, Alan & Rush, Bonnie, 2003. "Can willingness to pay capture the value of altruism? An exploration of Sen's notion of commitment," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 32(6), pages 647-660, December.
  21. Sean P. Gavan & Stuart J. Wright & Fiona Thistlethwaite & Katherine Payne, 2023. "Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review," PharmacoEconomics, Springer, vol. 41(6), pages 675-692, June.
  22. Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011. "The impact of comparative effectiveness research on health and health care spending," Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
  23. Basu, Anirban & Meltzer, David, 2005. "Implications of spillover effects within the family for medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 24(4), pages 751-773, July.
  24. Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock, 2018. "Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 341-353, April.
  25. A. E. Ades & G. Lu & K. Claxton, 2004. "Expected Value of Sample Information Calculations in Medical Decision Modeling," Medical Decision Making, , vol. 24(2), pages 207-227, March.
  26. Juliane Andrea Duevel & Lena Hasemann & Luz María Peña-Longobardo & Beatriz Rodríguez-Sánchez & Isaac Aranda-Reneo & Juan Oliva-Moreno & Julio López-Bastida & Wolfgang Greiner, 2020. "Considering the societal perspective in economic evaluations: a systematic review in the case of depression," Health Economics Review, Springer, vol. 10(1), pages 1-19, December.
  27. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  28. P. Pedram Sendi & Andrew H. Briggs, 2001. "Affordability and cost‐effectiveness: decision‐making on the cost‐effectiveness plane," Health Economics, John Wiley & Sons, Ltd., vol. 10(7), pages 675-680, October.
  29. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
  30. Morris Meisner & Eugene M. Laska & Carole Siegel & Joseph Wanderling, 2002. "The familywise error rate of a simultaneous confidence band for the incremental net health benefit," Health Economics, John Wiley & Sons, Ltd., vol. 11(3), pages 275-280, April.
  31. Raymond C.W. Hutubessy & Rob M.P.M. Baltussen & David B. Evans & Jan J. Barendregt & Christopher J.L. Murray, 2001. "Stochastic league tables: communicating cost‐effectiveness results to decision‐makers," Health Economics, John Wiley & Sons, Ltd., vol. 10(5), pages 473-477, July.
  32. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
  33. Judit Simon & Noemi Kiss & Kees Korrelboom & David Kingdon & Til Wykes & Peter Phiri & Mark van der Gaag & M. Fazil Baksh & Craig Steel, 2022. "Cost-Effectiveness of Positive Memory Training (PoMeT) for the Treatment of Depression in Schizophrenia," IJERPH, MDPI, vol. 19(19), pages 1-13, September.
  34. Matt D. Stevenson & Myfanwy Lloyd Jones, 2011. "The Cost Effectiveness of a Randomized Controlled Trial to Establish the Relative Efficacy of Vitamin K1 Compared with Alendronate," Medical Decision Making, , vol. 31(1), pages 43-52, January.
  35. Helen Dakin & Morris Sherman & Scott Fung & Carrie Fidler & Anthony Bentley, 2011. "Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective," PharmacoEconomics, Springer, vol. 29(12), pages 1075-1091, December.
  36. Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach, 2012. "Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(3), pages 237-250, June.
  37. Haitham Tuffaha & Shelley Roberts & Wendy Chaboyer & Louisa Gordon & Paul Scuffham, 2015. "Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 167-179, April.
  38. Nandita Mitra & Alka Indurkhya, 2005. "A propensity score approach to estimating the cost–effectiveness of medical therapies from observational data," Health Economics, John Wiley & Sons, Ltd., vol. 14(8), pages 805-815, August.
  39. Moreno, E. & Girón, F.J. & Martínez, M.L. & Vázquez-Polo, F.J. & Negrín, M.A., 2013. "Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition," European Journal of Operational Research, Elsevier, vol. 226(1), pages 173-182.
  40. O'Neill, Donal, 2009. "A Cost-Benefit Analysis of Early Childhood Intervention: Evidence from a Randomised Evaluation of a Parenting Programme," IZA Discussion Papers 4518, Institute of Labor Economics (IZA).
  41. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
  42. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023.
  43. Dirk Mueller & Afschin Gandjour, 2008. "Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 113-135, July.
  44. Neil Hawkins & David A. Scott, 2011. "Reimbursement and value‐based pricing: stratified cost‐effectiveness analysis may not be the last word," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 688-698, June.
  45. Thomas Michael Otten & Sabine E. Grimm & Bram Ramaekers & Manuela A. Joore, 2023. "Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations," PharmacoEconomics, Springer, vol. 41(6), pages 619-632, June.
  46. Sriubaite, I. & Harris, A. & Jones, A.M. & Gabbe, B., 2020. "Economic Consequences of Road Traffic Injuries. Application of the Super Learner algorithm," Health, Econometrics and Data Group (HEDG) Working Papers 20/20, HEDG, c/o Department of Economics, University of York.
  47. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
  48. Andrew H. Briggs & Bernie J. O'Brien, 2001. "The death of cost‐minimization analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 10(2), pages 179-184, March.
  49. Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour, 2003. "Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 21(1), pages 39-48, January.
  50. Lynch, Frances L. & Dickerson, John F. & Pears, Katherine C. & Fisher, Philip A., 2017. "Cost effectiveness of a school readiness intervention for foster children," Children and Youth Services Review, Elsevier, vol. 81(C), pages 63-71.
  51. Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs, 2000. "Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling," Working Papers 179chedp, Centre for Health Economics, University of York.
  52. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
  53. Palmer, Stephen & Smith, Peter C., 2000. "Incorporating option values into the economic evaluation of health care technologies," Journal of Health Economics, Elsevier, vol. 19(5), pages 755-766, September.
  54. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & Negrín, M.A., 2012. "Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis," European Journal of Operational Research, Elsevier, vol. 218(2), pages 512-522.
  55. Thomas Kenworthy & W. Edward McMullan, 2013. "Finding Practical Knowledge in Entrepreneurship," Entrepreneurship Theory and Practice, , vol. 37(5), pages 983-997, September.
  56. Jordan Amdahl & Jose Diaz & Arati Sharma & Jinhee Park & David Chandiwana & Thomas E Delea, 2017. "Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom," PLOS ONE, Public Library of Science, vol. 12(6), pages 1-18, June.
  57. Mickael Löthgren & Niklas Zethraeus, 2000. "Definition, interpretation and calculation of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 9(7), pages 623-630, October.
  58. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
  59. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & NegrI´n, M.A., 2010. "Optimal healthcare decisions: Comparing medical treatments on a cost-effectiveness basis," European Journal of Operational Research, Elsevier, vol. 204(1), pages 180-187, July.
  60. Karl Claxton, 2007. "Oft, Vbp: Qed?," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 545-558, June.
  61. Anna Heath & Natalia Kunst & Christopher Jackson & Mark Strong & Fernando Alarid-Escudero & Jeremy D. Goldhaber-Fiebert & Gianluca Baio & Nicolas A. Menzies & Hawre Jalal, 2020. "Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies," Medical Decision Making, , vol. 40(3), pages 314-326, April.
  62. Ya-Chen Tina Shih & Shu Han & Scott B. Cantor, 2005. "Impact of Generic Drug Entry on Cost-Effectiveness Analysis," Medical Decision Making, , vol. 25(1), pages 71-80, January.
  63. P. Sendi & A. Gafni & S. Birch, 2002. "Opportunity costs and uncertainty in the economic evaluation of health care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 23-31, January.
  64. Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
  65. Jeffrey Hoch & Carolyn Dewa, 2007. "Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions," PharmacoEconomics, Springer, vol. 25(10), pages 807-816, October.
  66. John Mullahy, 2017. "Individual Results May Vary: Elementary Analytics of Inequality-Probability Bounds, with Applications to Health-Outcome Treatment Effects," NBER Working Papers 23603, National Bureau of Economic Research, Inc.
  67. Kaatje Bollaerts & Tom Smedt & Katherine Donegan & Lina Titievsky & Vincent Bauchau, 2018. "Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project," Drug Safety, Springer, vol. 41(8), pages 775-786, August.
  68. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  69. Paul C. Lambert & Lucinda J. Billingham & Nicola J. Cooper & Alex J. Sutton & Keith R. Abrams, 2008. "Estimating the cost‐effectiveness of an intervention in a clinical trial when partial cost information is available: a Bayesian approach," Health Economics, John Wiley & Sons, Ltd., vol. 17(1), pages 67-81, January.
  70. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for Timing when Assessing Health-Related Policies," Journal of Benefit-Cost Analysis, Cambridge University Press, vol. 10(S1), pages 73-105, April.
  71. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4, January.
  72. Felix Achana & Stavros Petrou & Kamran Khan & Amadou Gaye & Neena Modi, 2018. "A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 75-86, January.
  73. Lynch, Frances L. & Dickerson, John F. & Saldana, Lisa & Fisher, Phillip A., 2014. "Incremental net benefit of early intervention for preschool-aged children with emotional and behavioral problems in foster care," Children and Youth Services Review, Elsevier, vol. 36(C), pages 213-219.
  74. M. Botteman & M. Meijboom & I. Foley & J. Stephens & Y. Chen & S. Kaura, 2011. "Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(6), pages 575-588, December.
  75. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
  76. Helen Dakin & Sarah Wordsworth, 2013. "Cost‐Minimisation Analysis Versus Cost‐Effectiveness Analysis, Revisited," Health Economics, John Wiley & Sons, Ltd., vol. 22(1), pages 22-34, January.
  77. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
  78. Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden, 2021. "Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier," PharmacoEconomics, Springer, vol. 39(1), pages 19-24, January.
  79. Basu, Anirban, 2011. "Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care," Journal of Health Economics, Elsevier, vol. 30(3), pages 549-559, May.
  80. David Brain & Laith Yakob & Adrian Barnett & Thomas Riley & Archie Clements & Kate Halton & Nicholas Graves, 2018. "Economic evaluation of interventions designed to reduce Clostridium difficile infection," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-15, January.
  81. Mike Paulden, 2020. "Why it’s Time to Abandon the ICER," PharmacoEconomics, Springer, vol. 38(8), pages 781-784, August.
  82. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
  83. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
  84. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
  85. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
  86. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440, March.
  87. Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman, 2007. "It’s Time to Choose the Study Design!," PharmacoEconomics, Springer, vol. 25(11), pages 903-911, November.
  88. Fleurence, Rachael L. & Torgerson, David J., 2004. "Setting priorities for research," Health Policy, Elsevier, vol. 69(1), pages 1-10, July.
  89. Simon Eckermann & Tim Coelli, 2008. "Including quality attributes in a model of health care efficiency: A net benefit approach," CEPA Working Papers Series WP032008, School of Economics, University of Queensland, Australia.
  90. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.
  91. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
  92. Claxton, Karl, 1999. "The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies," Journal of Health Economics, Elsevier, vol. 18(3), pages 341-364, June.
  93. Pedram Sendi, 2021. "Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve," PharmacoEconomics, Springer, vol. 39(2), pages 161-169, February.
  94. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
  95. Judith E Bosmans & Veerle M H Coupé & Bart J Knottnerus & Suzanne E Geerlings & Eric P Moll van Charante & Gerben ter Riet, 2017. "Cost-effectiveness of different strategies for diagnosis of uncomplicated urinary tract infections in women presenting in primary care," PLOS ONE, Public Library of Science, vol. 12(11), pages 1-16, November.
  96. Zou, Guang Yong & Taleban, Julia & Huo, Cindy Y., 2009. "Confidence interval estimation for lognormal data with application to health economics," Computational Statistics & Data Analysis, Elsevier, vol. 53(11), pages 3755-3764, September.
  97. Nicholas Illenberger & Nandita Mitra & Andrew J. Spieker, 2022. "A regression framework for a probabilistic measure of cost‐effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 31(7), pages 1438-1451, July.
  98. Eckermann, Simon & Coelli, Tim, 2013. "Including quality attributes in efficiency measures consistent with net benefit: Creating incentives for evidence based medicine in practice," Social Science & Medicine, Elsevier, vol. 76(C), pages 159-168.
  99. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 1)," PharmacoEconomics, Springer, vol. 29(3), pages 189-198, March.
  100. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
  101. Bas Groot Koerkamp & M. G. Myriam Hunink & Theo Stijnen & Milton C. Weinstein, 2006. "Identifying key parameters in cost‐effectiveness analysis using value of information: a comparison of methods," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 383-392, April.
  102. David M. Phillippo & Sofia Dias & A. E. Ades & Vanessa Didelez & Nicky J. Welton, 2018. "Sensitivity of treatment recommendations to bias in network meta‐analysis," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 181(3), pages 843-867, June.
  103. Nikki McCaffrey & Meera Agar & Janeane Harlum & Jonathon Karnon & David Currow & Simon Eckermann, 2015. "Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-19, March.
  104. Martin Henriksson & Fredrik Lundgren & Per Carlsson, 2006. "Informing the efficient use of health care and health care research resources ‐ the case of screening for abdominal aortic aneurysm in Sweden," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1311-1322, December.
  105. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
  106. Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore, 2007. "Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients," PharmacoEconomics, Springer, vol. 25(3), pages 239-251, March.
  107. Douglas Coyle, 2003. "Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 159-162, February.
  108. Eugene M. Laska & Morris Meisner & Carole Siegel & Joseph Wanderling, 2002. "Statistical determination of cost‐effectiveness frontier based on net health benefits," Health Economics, John Wiley & Sons, Ltd., vol. 11(3), pages 249-264, April.
  109. Tinelli, Michela & Roddy, Áine & Knapp, Martin & Arango, Celso & Mendez, Maria Andreina & Cusack, James & Canitano, Roberto & Oakley, Bethany & Quoidbach, Vinciane, 2023. "Economic analysis of early intervention for autistic children: findings from four case studies in England, Ireland, Italy and Spain," LSE Research Online Documents on Economics 119943, London School of Economics and Political Science, LSE Library.
  110. Janne Martikainen & Hannu Valtonen & Tuula Pirttilä, 2004. "Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 136-142, May.
  111. Jing Voon Chen & Julia L. Higle & Michael Hintlian, 2018. "A systematic approach for examining the impact of calibration uncertainty in disease modeling," Computational Management Science, Springer, vol. 15(3), pages 541-561, October.
  112. Clarke, Philip M. & Hayes, Alison J., 2009. "Measuring achievement: Changes in risk factors for cardiovascular disease in Australia," Social Science & Medicine, Elsevier, vol. 68(3), pages 552-561, February.
  113. Meltzer, David, 2001. "Addressing uncertainty in medical cost-effectiveness analysis: Implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to s," Journal of Health Economics, Elsevier, vol. 20(1), pages 109-129, January.
  114. Daniel F. Heitjan, 2000. "Fieller's method and net health benefits," Health Economics, John Wiley & Sons, Ltd., vol. 9(4), pages 327-335, June.
  115. Daniel Howdon & James Lomas, 2017. "Pricing implications of non-marginal budgetary impacts in health technology assessment: a conceptual model," Working Papers 148cherp, Centre for Health Economics, University of York.
  116. Simon Eckermann & Andrew R. Willan, 2009. "Globally optimal trial design for local decision making," Health Economics, John Wiley & Sons, Ltd., vol. 18(2), pages 203-216, February.
  117. Elamin H. Elbasha, 2005. "Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 457-470, May.
  118. John Mullahy, 2001. "Live long, live well: quantifying the health of heterogeneous populations," Health Economics, John Wiley & Sons, Ltd., vol. 10(5), pages 429-440, July.
  119. Anthony O’Hagan & John Stevens & Jacques Montmartin, 2000. "Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio," PharmacoEconomics, Springer, vol. 17(4), pages 339-349, April.
  120. Dirk Müller & Lisa Borsi & Claudia Stracke & Stephanie Stock & Björn Stollenwerk, 2015. "Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(5), pages 517-527, June.
  121. Anthony O'Hagan & John W. Stevens, 2001. "A framework for cost‐effectiveness analysis from clinical trial data," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 303-315, June.
  122. Phillip Dinh & Xiao-Hua Zhou, 2006. "Nonparametric Statistical Methods for Cost-Effectiveness Analyses," Biometrics, The International Biometric Society, vol. 62(2), pages 576-588, June.
  123. Heather Catt & Keith Bodger & Jamie J. Kirkham & Dyfrig A. Hughes, 2019. "Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease," PharmacoEconomics, Springer, vol. 37(12), pages 1509-1523, December.
  124. Ana P. Johnson-Masotti & Purushottam W. Laud & Raymond G. Hoffmann & Matthew J. Hayat & Steven D. Pinkerton, 2001. "Probabilistic Cost-Effectiveness Analysis of HIV Prevention," Evaluation Review, , vol. 25(4), pages 474-502, August.
  125. Pinkerton, Steven D. & Johnson-Masotti, Ana P. & Derse, Arthur & Layde, Peter M., 2002. "Ethical issues in cost-effectiveness analysis," Evaluation and Program Planning, Elsevier, vol. 25(1), pages 71-83, February.
  126. Nicola E Stanczyk & Eline S Smit & Daniela N Schulz & Hein de Vries & Catherine Bolman & Jean W M Muris & Silvia M A A Evers, 2014. "An Economic Evaluation of a Video- and Text-Based Computer-Tailored Intervention for Smoking Cessation: A Cost-Effectiveness and Cost-Utility Analysis of a Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-14, October.
  127. Brennan, Alan & Kharroubi, Samer A., 2007. "Efficient computation of partial expected value of sample information using Bayesian approximation," Journal of Health Economics, Elsevier, vol. 26(1), pages 122-148, January.
  128. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
  129. Fabienne Abadie & Christian Boehler, 2015. "Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) - Conceptual description of the Monitoring and Assessment Framework for the EIP on AHA," JRC Research Reports JRC96205, Joint Research Centre.
  130. Bebu, Ionut & Luta, George & Mathew, Thomas & Kennedy, Paul A. & Agan, Brian K., 2016. "Parametric cost-effectiveness inference with skewed data," Computational Statistics & Data Analysis, Elsevier, vol. 94(C), pages 210-220.
  131. Lazaros Andronis & Lucinda J. Billingham & Stirling Bryan & Nicholas D. James & Pelham M. Barton, 2016. "A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research," Medical Decision Making, , vol. 36(3), pages 321-334, April.
  132. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of 'payback' and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357.
  133. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
  134. Casey Quinn, 2005. "Generalisable regression methods for costeffectiveness using copulas," Health, Econometrics and Data Group (HEDG) Working Papers 05/13, HEDG, c/o Department of Economics, University of York.
  135. Todd H. Wagner & Jean Yoon & Josephine C. Jacobs & Angela So & Amy M. Kilbourne & Wei Yu & David E. Goodrich, 2020. "Estimating Costs of an Implementation Intervention," Medical Decision Making, , vol. 40(8), pages 959-967, November.
  136. Eugene M. Laska & Morris Meisner & Carole Siegel, 1999. "Power and Sample Size in Cost- Effectiveness Analysis," Medical Decision Making, , vol. 19(3), pages 339-343, August.
  137. David J. Vanness & John Mullahy, 2012. "Moving Beyond Mean-based Evaluation of Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 52, Edward Elgar Publishing.
  138. Mike Paulden, 2020. "Calculating and Interpreting ICERs and Net Benefit," PharmacoEconomics, Springer, vol. 38(8), pages 785-807, August.
  139. Victor van der Meer & Wilbert B van den Hout & Moira J Bakker & Klaus F Rabe & Peter J Sterk & Willem J J Assendelft & Job Kievit & Jacob K Sont & on behalf of the SMASHING (Self-Management in Asthma , 2011. "Cost-Effectiveness of Internet-Based Self-Management Compared with Usual Care in Asthma," PLOS ONE, Public Library of Science, vol. 6(11), pages 1-8, November.
  140. Daniel F. Heitjan & Huiling Li, 2004. "Bayesian estimation of cost‐effectiveness: an importance‐sampling approach," Health Economics, John Wiley & Sons, Ltd., vol. 13(2), pages 191-198, February.
  141. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
  142. Quang Dang Nguyen & Mikhail Prokopenko, 2022. "A general framework for optimising cost-effectiveness of pandemic response under partial intervention measures," Papers 2205.08996, arXiv.org, revised Nov 2022.
  143. Caterina Conigliani & Andrea Tancredi, 2009. "A Bayesian model averaging approach for cost‐effectiveness analyses," Health Economics, John Wiley & Sons, Ltd., vol. 18(7), pages 807-821, July.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.